

chain nodes :

7 8 9 10 11

ring nodes :

1 2 3 4 5 6

chain bonds :

1-11 2-7 4-10 5-8 7-9

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

1-11 2-7 4-10 7-9

exact bonds :

5-8


normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:CLASS 10:CLASS
11:CLASS

~~14~~
GI ANSWER 1 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN



AB Title compds. [I; R1, R2 = halo, NO₂, CN, Ra, ORa, SORa, NRaRa, CONRaRa, CSNRaRa, SORaRa, NRaSORa, NRaCO₂Ra, NRaC(S)ORa, O₂CNRaRa, OC(S)NRaRa, NRaCONRaRa, NRaCSNRaRa, CO₂Ra, C(S)ORa, O₂CORa, CRaRaAr; X = NR₃R₄, OR₃, CR₃R₄R₅, COR₃, CSR₃, SOR₃, NR₃COR₄, NR₃CSR₄, NR₃SOR₄, R₃; R₃-R₅ = Ra, substituted A, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylcycloalkyl, heteroarylcycloalkyl, arylheterocycloalkyl, heteroarylheterocycloalkyl; Ra = H, A, cycloalkyl, haloalkyl, aryl, heteroaryl, heterocycloalkyl, where Ra may be substituted with 1-5 of Rt, ORt, SORt, NRtRt, O, S; Rt = H, halo, NO₂, NH₂, OH, SH, CN, CONH₂, CSNH₂, CONHA, CSNHA, CONA₂, CSNA₂, OA, NHA, NA₂, SORa, SO₂NH₂, SO₂NHA, SO₂NA₂, A, cycloalkyl, haloalkyl, Ph, PhCH₂, heteroaryl, heterocycloalkyl where Ph, PhCH₂, heteroaryl, heterocycloalkyl may be substituted with A, halo; G = Q1, Q2 (substituted) by halo, CN, NO₂, O, S, OR₅, SR₅, NR₅R₅, COR₅, C(S)R₅, CO₂R₅, C(S)OR₅, CONR₅R₅, CSNR₅R₅, SOR₅, SO₂NR₅R₅, NR₅COR₅, NR₅CSR₅, NR₅CO₂R₅, NR₅C(S)OR₅, NR₅CONR₅R₅, NR₅CSNR₅R₅, NR₅SO₂R₅, O₂CR₅, OC(S)R₅, OC(O)OR₅, OC(S)OR₅, O₂CNR₅R₅, OC(S)NR₅R₅, CR₅R₅Ar, (substituted) A, cycloalkyl, aryl, heteroaryl, heterocycloalkyl; G groups may contain 1 double bond in its nonarom. ring; Ar = (substituted) aryl, heteroaryl; A = alkyl; m, n = 0-2], were prepd. as CRF1 receptor antagonists (no data). Thus, 5-bromo-3,6-diethyl-N-(1-ethylpropyl)pyrazin-2-amine (prepn. given), 6-methoxy-2,3-dihydro-1H-inden-5-ylboronic acid (prepn. given), tetrakis(triphenylphosphine)palladium(0), 2M Na₂CO₃, and ethylene glycol di-Me ether were heated together on an orbital shaker at 80.degree. for 30 h to give 66% 3,6-diethyl-N-(1-ethylpropyl)-5-(6-methoxy-2,3-dihydro-1H-inden-5-yl)pyrazin-2-amine.

ACCESSION NUMBER: 2003:875261 CAPLUS
DOCUMENT NUMBER: 139:381508
TITLE: Preparation of pyrazines as CRF1 receptor antagonists.
INVENTOR(S): Corbett, Jeffrey W.; Ennis, Michael D.; Frank, Kristine E.; Fu, Jian-Min; Hoffman, Robert L.; Verhoest, Patrick R.
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 124 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003091225	A1	20031106	WO 2003-US10474	20030417
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				

PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD,
RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2002-376031P P 20020426

OTHER SOURCE(S): MARPAT 139:381508


IT 622833-81-2P 622833-82-3P 622833-83-4P
622833-84-5P 622833-85-6P 622833-86-7P
622833-87-8P 622833-88-9P 622833-89-0P
622833-90-3P 622833-92-5P 622833-93-6P
622833-94-7P 622833-95-8P 622833-96-9P
622833-97-0P 622833-98-1P 622834-00-8P
622834-01-9P 622834-02-0P 622834-05-3P
622834-06-4P 622834-07-5P 622834-08-6P
622834-09-7P 622834-10-0P 622834-11-1P
622834-12-2P 622834-13-3P 622834-14-4P
622834-15-5P 622834-17-7P 622834-18-8P
622834-19-9P 622834-20-2P 622834-21-3P
622834-22-4P 622834-23-5P 622834-26-8P
622834-27-9P 622834-28-0P 622834-33-7P
622834-34-8P 622834-35-9P 622834-36-0P
622834-37-1P 622834-38-2P 622834-39-3P
622834-40-6P 622834-41-7P 622834-42-8P
622834-44-0P 622834-45-1P 622834-46-2P
622834-47-3P 622834-48-4P 622834-49-5P
622834-50-8P 622834-51-9P 622834-52-0P
622834-53-1P 622834-54-2P 622834-55-3P
622834-56-4P 622834-57-5P 622834-59-7P
622834-60-0P 622834-61-1P 622834-62-2P
622834-63-3P 622834-64-4P 622834-65-5P
622834-66-6P 622834-67-7P 622834-68-8P
622834-69-9P 622834-70-2P 622834-71-3P
622834-72-4P 622834-73-5P 622834-74-6P
622834-75-7P 622834-76-8P 622834-77-9P
622834-78-0P 622834-79-1P 622834-80-4P
622834-81-5P 622834-82-6P 622834-83-7P
622834-84-8P 622834-85-9P 622834-87-1P
622834-88-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(claimed compd.; prepn. of pyrazines as CRF1 receptor antagonists)

RN 622833-81-2 CAPLUS


CN Pyrazinamine, 5-(2,3-dihydro-4-methoxy-7-methyl-1H-inden-5-yl)-3,6-diethyl-
N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)






RN 622833-82-3 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(5,6,7,8-tetrahydro-2-methoxy-1-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 622833-83-4 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(5,6,7,8-tetrahydro-4-methoxy-1-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 622833-84-5 CAPLUS

CN Pyrazinamine, 5-(2-ethoxy-5,6,7,8-tetrahydro-1-naphthalenyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 622833-85-6 CAPLUS

CN 2-Naphthalenol, 3-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)




RN 622833-86-7 CAPLUS

CN Methanesulfonic acid, trifluoro-, 3-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-5,6,7,8-tetrahydro-2-naphthalenyl ester (9CI)
(CA INDEX NAME)




RN 622833-87-8 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(5,6,7,8-tetrahydro-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 622833-88-9 CAPLUS

CN Pyrazinamine, 5-(3-chloro-5,6,7,8-tetrahydro-2-naphthalenyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 622833-89-0 CAPLUS

CN Pyrazinamine, 5-(2,3-dihydro-6-methoxy-1H-inden-5-yl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)



RN 622833-90-3 CAPLUS

CN Pyrazinamine, 5-(2,3-dihydro-6-methoxy-1H-inden-5-yl)-3,6-diethyl-N-[2-methoxy-1-(methoxymethyl)ethyl]- (9CI) (CA INDEX NAME)




RN 622833-92-5 CAPLUS

CN Pyrazinamine, 5-(2,3-dihydro-6-methoxy-1H-inden-5-yl)-3,6-diethyl-N-[(1R)-

1-(methoxymethyl)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622833-93-6 CAPLUS

CN Pyrazinamine, 5-(2,3-dihydro-6-methoxy-1H-inden-5-yl)-N-[(1S)-1-(ethoxymethyl)propyl]-3,6-diethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622833-94-7 CAPLUS

CN Pyrazinamine, 5-(2,3-dihydro-6-methoxy-1H-inden-5-yl)-3,6-diethyl-N-[(1S)-1-[(2-fluoroethoxy)methyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622833-95-8 CAPLUS

CN Pyrazinamine, 5-(2,3-dihydro-6-methoxy-1H-inden-5-yl)-3,6-diethyl-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622833-96-9 CAPLUS

CN Pyrazinamine, 5-(2,3-dihydro-6-methoxy-1H-inden-5-yl)-3,6-diethyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622833-97-0 CAPLUS

CN Pyrazinamine, 5-(2,3-dihydro-6-methoxy-1H-inden-5-yl)-3,6-diethyl-N-[(1R)-1-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 622833-98-1 CAPLUS


CN Pyrazinamine, 5-(2,3-dihydro-6-methoxy-1H-inden-5-yl)-3,6-diethyl-N-[(1S)-1-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 622834-00-8 CAPLUS

CN Pyrazinamine, N-(dicyclopropylmethyl)-5-(2,3-dihydro-6-methoxy-1H-inden-5-yl)-3,6-diethyl- (9CI) (CA INDEX NAME)




RN 622834-01-9 CAPLUS


CN Pyrazinamine, 5-(2,3-dihydro-6-methoxy-1H-inden-5-yl)-3,6-diethyl-N-(1-methylbutyl)- (9CI) (CA INDEX NAME)



RN 622834-02-0 CAPLUS


CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(5,6,7,8-tetrahydro-3-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)





RN 622834-05-3 CAPLUS


CN Pyrazinamine, 3,6-diethyl-N-[2-methoxy-1-(methoxymethyl)ethyl]-5-(5,6,7,8-tetrahydro-3-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 622834-06-4 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-[(1R)-1-(methoxymethyl)propyl]-5-(5,6,7,8-tetrahydro-3-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622834-07-5 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-[(1S)-1-(methoxymethyl)propyl]-5-(5,6,7,8-tetrahydro-3-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622834-08-6 CAPLUS

CN Pyrazinamine, N-[(1S)-1-(ethoxymethyl)propyl]-3,6-diethyl-5-(5,6,7,8-tetrahydro-3-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622834-09-7 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-[(1S)-1-[(2-fluoroethoxy)methyl]propyl]-5-(5,6,7,8-tetrahydro-3-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622834-10-0 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-[(1R)-1-phenylethyl]-5-(5,6,7,8-tetrahydro-3-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622834-11-1 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-[(1S)-1-phenylethyl]-5-(5,6,7,8-tetrahydro-3-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622834-12-2 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-[(1R)-1-methylpropyl]-5-(5,6,7,8-tetrahydro-3-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 622834-13-3 CAPLUS


CN Pyrazinamine, 3,6-diethyl-N-[(1S)-1-methylpropyl]-5-(5,6,7,8-tetrahydro-3-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 622834-14-4 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-(2-ethylbutyl)-5-(5,6,7,8-tetrahydro-3-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 622834-15-5 CAPLUS

CN Pyrazinamine, N-(dicyclopropylmethyl)-3,6-diethyl-5-(5,6,7,8-tetrahydro-3-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 622834-17-7 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-(1-propylbutyl)-5-(5,6,7,8-tetrahydro-3-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 622834-18-8 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-(1-methylbutyl)-5-(5,6,7,8-tetrahydro-3-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 622834-19-9 CAPLUS

CN Butanoic acid, 3-[[3,6-diethyl-5-(5,6,7,8-tetrahydro-3-methoxy-2-naphthalenyl)pyrazinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 622834-20-2 CAPLUS

CN 1-Butanol, 3-[[3,6-diethyl-5-(5,6,7,8-tetrahydro-3-methoxy-2-naphthalenyl)pyrazinyl]amino]- (9CI) (CA INDEX NAME)




RN 622834-21-3 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-(3-methoxy-1-methylpropyl)-5-(5,6,7,8-tetrahydro-3-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 622834-22-4 CAPLUS

CN Pyrazinamine, N-(3-ethoxy-1-methylpropyl)-3,6-diethyl-5-(5,6,7,8-tetrahydro-3-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 622834-23-5 CAPLUS

CN 1-Butanol, 3-[[3,6-diethyl-5-(5,6,7,8-tetrahydro-3-methoxy-2-naphthalenyl)pyrazinyl]amino]-, acetate (ester) (9CI) (CA INDEX NAME)




RN 622834-26-8 CAPLUS

CN 1H-Inden-1-one, 5-[3,6-diethyl-5-[(1-ethylpropyl)aminopyrazinyl]-2,3-dihydro-6-methoxy- (9CI) (CA INDEX NAME)




RN 622834-27-9 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(6-ethynyl-2,3-dihydro-1H-inden-5-yl)- (9CI) (CA INDEX NAME)




RN 622834-28-0 CAPLUS

CN 1H-Inden-1-one, 5-[3,6-diethyl-5-[(1-ethylpropyl)aminopyrazinyl]-2,3-dihydro-2-hydroxy-6-methoxy-2-methyl- (9CI) (CA INDEX NAME)




RN 622834-33-7 CAPLUS

CN Pyrazinamine, 5-(2,3-dihydro-4-methoxy-1H-inden-5-yl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 622834-34-8 CAPLUS

CN Pyrazinamine, 5-(2,3-dihydro-6-methoxy-4-methyl-1H-inden-5-yl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 622834-35-9 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(5-methoxy-1H-inden-6-yl)-
(9CI) (CA INDEX NAME)

RN 622834-36-0 CAPLUS


CN Pyrazinamine, 5-(5,6-dihydro-3-methoxy-2-naphthalenyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)



RN 622834-37-1 CAPLUS


CN Pyrazinamine, 5-(2,3-dihydro-6-methoxy-1H-inden-5-yl)-3,6-diethyl-N-[(1S,2S)-2-(methylamino)cyclopropyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 622834-38-2 CAPLUS


CN 1H-Indene-5-carbonitrile, 6-[3,6-diethyl-5-[(1-ethylpropyl)aminopyrazinyl]-2,3-dihydro- (9CI) (CA INDEX NAME)






RN 622834-39-3 CAPLUS

CN 1H-Inden-1-one, 6-[3,6-diethyl-5-[(1-ethylpropyl)amin]pyrazinyl]-2,3-dihydro-5-methoxy- (9CI) (CA INDEX NAME)




RN 622834-40-6 CAPLUS

CN 1(2H)-Naphthalenone, 6-[3,6-diethyl-5-[(1-ethylpropyl)amin]pyrazinyl]-3,4-dihydro-7-methoxy- (9CI) (CA INDEX NAME)




RN 622834-41-7 CAPLUS

CN 1H-Inden-1-ol, 5-[3,6-diethyl-5-[(1-ethylpropyl)amin]pyrazinyl]-2,3-dihydro-6-methoxy- (9CI) (CA INDEX NAME)




RN 622834-42-8 CAPLUS

CN Pyrazinamine, 5-(1-amino-2,3-dihydro-6-methoxy-1H-inden-5-yl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 622834-44-0 CAPLUS

CN Pyrazinamine, 5-(2,3-dihydro-6-methyl-1H-inden-5-yl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)



RN 622834-45-1 CAPLUS


CN Pyrazinamine, 5-(2,3-dihydro-6-methoxy-1H-inden-5-yl)-N-(1-ethylpropyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)



RN 622834-46-2 CAPLUS


CN 1H-Inden-1-one, 5-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-2,3-dihydro-6-methoxy-, oxime, (1E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 622834-47-3 CAPLUS

CN Pyrazinamine, 5-[2,3-dihydro-6-methoxy-1-(methylamino)-1H-inden-5-yl]-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 622834-48-4 CAPLUS

CN Acetamide, N-[5-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-2,3-dihydro-6-methoxy-1H-inden-1-yl]- (9CI) (CA INDEX NAME)




RN 622834-49-5 CAPLUS

CN Pyrazinamine, 5-(2,3-dihydro-1,6-dimethoxy-1H-inden-5-yl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)



RN 622834-50-8 CAPLUS


CN 1H-Inden-1-ol, 5-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-2,3-dihydro-6-methoxy-, acetate (ester) (9CI) (CA INDEX NAME)



RN 622834-51-9 CAPLUS


CN Urea, [5-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-2,3-dihydro-6-

methoxy-1H-inden-1-yl]- (9CI) (CA INDEX NAME)




RN 622834-52-0 CAPLUS

CN Ethanethioamide, N-[5-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-2,3-dihydro-6-methoxy-1H-inden-1-yl]- (9CI) (CA INDEX NAME)




RN 622834-53-1 CAPLUS

CN 1H-Inden-1-one, 5-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-6-fluoro-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 622834-54-2 CAPLUS

CN 1H-Inden-1-ol, 5-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-2,3-dihydro-6-methoxy-1-methyl- (9CI) (CA INDEX NAME)




RN 622834-55-3 CAPLUS

CN 1H-Inden-1-one, 5-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-6-methoxy- (9CI) (CA INDEX NAME)




RN 622834-56-4 CAPLUS

CN 2H-Inden-2-one, 5-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-1,3-dihydro-6-methoxy- (9CI) (CA INDEX NAME)




RN 622834-57-5 CAPLUS

CN 1H-Indene-1,3(2H)-dione, 5-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-6-methoxy- (9CI) (CA INDEX NAME)




RN 622834-59-7 CAPLUS

CN 1H-Indene-1-thione, 5-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-2,3-dihydro-6-methoxy- (9CI) (CA INDEX NAME)




RN 622834-60-0 CAPLUS

CN 1H-Inden-1-one, 5-[6-ethyl-5-[(1-ethylpropyl)amino]-3-methylpyrazinyl]-2,3-dihydro-6-methoxy- (9CI) (CA INDEX NAME)




RN 622834-61-1 CAPLUS

CN 1H-Indene-1-thione, 5-[3-ethyl-5-[(1-ethylpropyl)amino]-6-(methoxymethyl)pyrazinyl]-2,3-dihydro-6-methoxy- (9CI) (CA INDEX NAME)




RN 622834-62-2 CAPLUS

CN 1H-Indene-1-thione, 5-[6-ethyl-5-[(1-ethylpropyl)amino]-3-(methoxymethyl)pyrazinyl]-2,3-dihydro-6-methoxy- (9CI) (CA INDEX NAME)




RN 622834-63-3 CAPLUS

CN 2-Propanone, 1-[[5-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-2,3-dihydro-6-methoxy-1H-inden-1-yl]oxy]- (9CI) (CA INDEX NAME)




RN 622834-64-4 CAPLUS

CN Ethanethioamide, 2-[[5-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-2,3-dihydro-6-methoxy-1H-inden-1-yl]oxy]- (9CI) (CA INDEX NAME)




RN 622834-65-5 CAPLUS

CN Pyrazinamine, 5-(2,3-dihydro-6-methoxy-1H-inden-5-yl)-3,6-diethyl-N-(1-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 622834-66-6 CAPLUS

CN 1H-Inden-1-one, 5-[3,6-diethyl-5-[(1-phenylpropyl)amino]pyrazinyl]-2,3-dihydro-6-methoxy- (9CI) (CA INDEX NAME)




RN 622834-67-7 CAPLUS

CN 1H-Inden-1-one, 5-[5-[(3-amino-1-methylpropyl)amino]-3,6-diethylpyrazinyl]-2,3-dihydro-6-methoxy- (9CI) (CA INDEX NAME)




RN 622834-68-8 CAPLUS

CN Urea, [3-[[5-(2,3-dihydro-6-methoxy-1H-inden-5-yl)-3,6-diethylpyrazinyl]amino]butyl]- (9CI) (CA INDEX NAME)




RN 622834-69-9 CAPLUS

CN Thiourea, [3-[[5-(2,3-dihydro-6-methoxy-1H-inden-5-yl)-3,6-diethylpyrazinyl]amino]butyl]- (9CI) (CA INDEX NAME)




RN 622834-70-2 CAPLUS

CN Pyrazinamine, 5-[6-(difluoromethoxy)-2,3-dihydro-1H-inden-5-yl]-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 622834-71-3 CAPLUS

CN Pyrazinamine, 5-[3-(difluoromethoxy)-5,6,7,8-tetrahydro-2-naphthalenyl]-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 622834-72-4 CAPLUS

CN Pyrazinamine, 5-[2,3-dihydro-6-(trifluoromethoxy)-1H-inden-5-yl]-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 622834-73-5 CAPLUS

CN Pyrazinamine, 5-[6-(difluoromethoxy)-2,3-dihydro-4-methoxy-1H-inden-5-yl]-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 622834-74-6 CAPLUS

CN Pyrazinamine, 5-(2,3-dihydro-4,6-dimethyl-1H-inden-5-yl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 622834-75-7 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(5,6,7,8-tetrahydro-1,3-dimethoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 622834-76-8 CAPLUS

CN Pyrazinamine, 5-[3-(difluoromethoxy)-5,6,7,8-tetrahydro-1-methoxy-2-naphthalenyl]-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 622834-77-9 CAPLUS

CN Pyrazinamine, 5-[4-[3-(dimethylamino)propyl]-2,3-dihydro-6-methoxy-1H-inden-5-yl]-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 622834-78-0 CAPLUS

CN Pyrazinamine, 5-[4-[2-(dimethylamino)ethoxy]-2,3-dihydro-6-methoxy-1H-inden-5-yl]-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 622834-79-1 CAPLUS

CN Pyrazinamine, 5-[2,3-dihydro-6-methoxy-4-[3-(4-morpholinyl)propyl]-1H-inden-5-yl]-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 622834-80-4 CAPLUS

CN Pyrazinamine, 5-(2,3-dihydro-6-methoxy-1H-inden-5-yl)-3,6-diethyl-N-[1-(2-pyridinyl)propyl]- (9CI) (CA INDEX NAME)




RN 622834-81-5 CAPLUS

CN Pyrazinamine, 5-(2,3-dihydro-6-methoxy-1H-inden-5-yl)-3,6-diethyl-N-(2-methoxy-1-phenylethyl)- (9CI) (CA INDEX NAME)




RN 622834-82-6 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-[1-(3-pyridinyl)propyl]-5-(5,6,7,8-tetrahydro-3-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 622834-83-7 CAPLUS

CN Benzenepropanol, .gamma.-[[3,6-diethyl-5-(5,6,7,8-tetrahydro-3-methoxy-2-naphthalenyl)pyrazinyl]amino]- (9CI) (CA INDEX NAME)




RN 622834-84-8 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-(3-methoxy-1-phenylpropyl)-5-(5,6,7,8-tetrahydro-3-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 622834-85-9 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(5-fluoro-7,8-dihydro-3-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 622834-87-1 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(1-fluoro-2,3-dihydro-6-methoxy-1H-inden-5-yl)- (9CI) (CA INDEX NAME)



RN 622834-88-2 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(2-fluoro-2,3-dihydro-6-methoxy-1H-inden-5-yl)- (9CI) (CA INDEX NAME)




IT 622834-97-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of pyrazines as CRF1 receptor antagonists)


RN 622834-97-3 CAPLUS

CN Pyrazinamine, 5-(3-amino-5,6,7,8-tetrahydro-2-naphthalenyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMATL4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
GI

AB Substituted aryl 1,4-pyrazine derivs. (shown as I; variables defined below; e.g. 5-(2,4-dichlorophenyl)-N-((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-3,6-diethylpyrazin-2-amine) and their use in treating anxiety disorders, depression and stress related disorders are disclosed. The binding affinity of I for the corticotropin releasing factor type I receptor expressed as IC₅₀ values generally ranges from .apprx.0.5 nM to .apprx.10 .mu.M; no specific values are given. Although the methods of prepn. are not claimed, 131 example preps. of I and 190 example preps. of intermediates are included. For I: X = -NR₃R₄, -OR₃, -CR₃R₅R₅, -C(O)R₃, -S(O)mR₃, -NR₃C(O)R₄, or -NR₃S(O)mR₄, m = 0-2; Ar = aryl, substituted aryl, heteroaryl, or substituted heteroaryl; R₁, R₂, and R₅ = halogen, -NO₂, -CN, -Ra, -ORa, -S(O)mRa, -NRaRa, -C(O)NRaRa, -C(S)NRaRa, -S(O)mNRaRa, -NRaS(O)mRa, -NRaC(O)ORa, -OC(O)NRaRa, -NRaC(O)NRaRa, -NRaC(S)NRaRa, -C(O)ORa, -C(S)ORa, or -OC(O)ORa. R₃ and R₄ = Ra or substituted and/or unsubstituted heterocycloalkyl, heteroaryl, aryl, aryl cycloalkyl, heteroaryl cycloalkyl, aryl heterocycloalkyl, or heteroaryl heterocycloalkyl; Ra = H, alkyl, cycloalkyl, haloalkyl, aryl, heteroaryl, or heterocycloalkyl (un)substituted with 1 to 5 of Rt, -ORt, -S(O)mRt, NRtRt, oxo, thione (:S), Ph, heteroaryl, or heterocycloalkyl; Rt = H, halogen, -NO₂, -NH₂, -OH, -SH, -CN, -C(O)NH₂, -C(O)NHalkyl, -C(O)Nalkylalkyl, -Oalkyl, NHalkyl, Nalkylalkyl, -S(O)malkyl, SO₂NH₂, SO₂NHalkyl and SO₂Nalkylalkyl, alkyl, cycloalkyl, haloalkyl, Ph, benzyl, heteroaryl, or heterocycloalkyl; addnl. details including specifically excluded compds. are given in the claims. Compds. I are also claimed effective for screening ligands for CRF1 receptors and for detecting CRF1 receptors in tissues.

ACCESSION NUMBER: 2003:434540 CAPLUS


DOCUMENT NUMBER: 139:6891

TITLE: Preparation of substituted aryl pyrazine derivatives
as CRF1 receptor antagonists useful against anxiety
disorders, depression and stress related disorders
INVENTOR(S): Verhoest, Patrick R.; Hoffman, Robert L.; Corbett,

Jeffrey W.; Ennis, Michael D.; Frank, Kristine E.; Fu,
Jian-Min
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 271 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003045924	A1	20030605	WO 2002-US33642	20021115
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR				
US 2003144297	A1	20030731	US 2002-298193	20021115
PRIORITY APPLN. INFO.:				
			US 2001-332052P	P 20011121
			US 2002-358546P	P 20020221
			US 2002-338285P	P 20020613
			US 2002-410378P	P 20020913
			US 2002-388285P	P 20020613
OTHER SOURCE(S): MARPAT 139:6891				
IT 535934-40-8P, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-((1S,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl)-N-methylpyrazin-2-amine 535934-44-2P, 5-(2,4-Dichlorophenyl)-3,6-diethyl-N-((1R,2R)-2-methoxy-2,3-dihydro-1H-inden-1-yl)-N-methylpyrazin-2-amine 535940-63-7P, 6-(2,4-Dichlorophenyl)-N-((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-N',N''-dimethylpyrazine-2,3,5-triamine 535940-65-9P, 3-(2,4-Dichlorophenyl)-N-((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-5-ethyl-N'-methylpyrazine-2,6-diamine RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses) (drug candidate and receptor detection and ligand screening agent; prepn. of substituted aryl pyrazine derivs. as CRF1 receptor antagonists useful against anxiety disorders, depression and stress related disorders)				
RN	535934-40-8	CAPLUS		
CN	Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1S,2S)-2,3-dihydro-2-methoxy-1H-inden-1-yl]-3,6-diethyl-N-methyl- (9CI) (CA INDEX NAME)			


Absolute stereochemistry.



RN 535934-44-2 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[(1R,2R)-2,3-dihydro-2-methoxy-1H-inden-1-yl]-3,6-diethyl-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535940-63-7 CAPLUS

CN Pyrazinetriamine, 6-(2,4-dichlorophenyl)-N2-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-N3,N5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 535940-65-9 CAPLUS

CN 2,6-Pyrazinediamine, 3-(2,4-dichlorophenyl)-N2-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-5-ethyl-N6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

AB 1,2,4-Triazine 4-oxides enter into the reactions of nucleophilic substitution of H with S-nucleophiles (arenethiols) in the presence of acylating agents and HO₂CCF₃. The reactions proceeded with loss of the N-oxide function to form 5-arylthio-1,2,4-triazines. 2-Amino-3-ethoxycarbonylpyrazine 1-oxides and 2-amino-4-oxopterine 8-oxides react with arenethiol analogously.

ACCESSION NUMBER: 2001:779514 CAPLUS


DOCUMENT NUMBER: 136:167353

TITLE: SNH reactions of 1,2,4-triazine N-oxides, pyrazine N-oxides, and pterin N-oxides with arenethiols


AUTHOR(S): Kozhevnikov, D. N.; Kovalev, I. S.; Rusinov, V. L.; Chupakhin, O. N.

CORPORATE SOURCE: Ural State Technical University, Yekaterinburg, 620002, Russia

SOURCE: Russian Chemical Bulletin (Translation of Izvestiya Akademii Nauk, Seriya Khimicheskaya) (2001), 50(6), 1068-1071
 CODEN: RCBUEY; ISSN: 1066-5285
 PUBLISHER: Kluwer Academic/Consultants Bureau
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 136:167353
 IT 396705-59-2P 396705-61-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (substitution reactions of 1,2,4-triazine N-oxides, pyrazine N-oxides, and pterin N-oxides with arenethiols)
 RN 396705-59-2 CAPLUS
 CN Pyrazinecarboxylic acid, 3-(benzoylamino)-6-phenyl-5-(phenylthio)-, ethyl ester (9CI) (CA INDEX NAME)




RN 396705-61-6 CAPLUS
 CN Pyrazinecarboxylic acid, 3-(acetylamino)-6-(4-methylphenyl)-5-(phenylthio)-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
 GI



AB Arylpyrazine compds. I [Ar = substituted Ph, naphthyl, heterocyclyl; R1, R3 = H, halo, cyano, NO₂, etc.; R2 = halo, amino, alkyl, etc.], including arylpyrazines that can bind with high affinity and high selectivity to CRF1 receptors, including human CRF1 receptors, were prepd. E.g., N-(1-ethylpropyl)-5-(2,4-dimethoxyphenyl)-3,6-dimethylpyrazine-2-amine was prepd. by reaction of 2-chloro-3,6-dimethylpyrazine with 1-ethylpropylamine, followed by bromination and reaction with 2,4-dimethoxybenzeneboronic acid.

ACCESSION NUMBER: 2001:617986 CAPLUS *applicant*
DOCUMENT NUMBER: 135:180787
TITLE: Preparation of substituted arylpyrazines and their binding with CRF1 receptors
INVENTOR(S): Yoon, Taeyoung; Ge, Ping; Horvath, Raymond F.; De Lombaert, Stephane; Hodgetts, Kevin J.; Doller, Dario; Zhang, Cunyu
PATENT ASSIGNEE(S): Neurogen Corporation, USA
SOURCE: PCT Int. Appl., 193 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001060806	A2	20010823	WO 2001-US5264	20010216
WO 2001060806	A3	20020207		
W:		AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
RW:		GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
EP 1255740	A2	20021113	EP 2001-910939	20010216
R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
US 2003018035	A1	20030123	US 2001-788315	20010216
EE 200200453	A	20031215	EE 2002-453	20010216
JP 2004500383	T2	20040108	JP 2001-560191	20010216
BG 106968	A	20030430	BG 2002-106968	20020731
NO 2002003869	A	20020911	NO 2002-3869	20020815
PRIORITY APPLN. INFO.:			US 2000-182934P P	20000216
			US 2000-206455P P	20000522
			WO 2001-US5264 W	20010216

OTHER SOURCE(S): MARPAT 135:180787


IT 355834-56-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT
(Reactant or reagent); USES (Uses)
(prepn. of substituted arylpyrazines and their binding with CRF1
receptors)

RN 355834-56-9 CAPLUS

CN Pyrazinamine, N-(1-ethylpropyl)-3,6-dimethyl-5-(2,4,6-trimethylphenyl)-
(9CI) (CA INDEX NAME)




IT 355834-36-5P 355834-37-6P 355834-38-7P
355834-39-8P 355834-40-1P 355834-41-2P
355834-44-5P 355834-45-6P 355834-46-7P
355834-47-8P 355834-48-9P 355834-49-0P
355834-50-3P 355834-51-4P 355834-52-5P
355834-53-6P 355834-54-7P 355834-55-8P
355834-57-0P 355834-58-1P 355834-59-2P
355834-60-5P 355834-61-6P 355834-62-7P
355834-63-8P 355834-64-9P 355834-65-0P
355834-66-1P 355834-67-2P 355834-68-3P
355834-69-4P 355834-70-7P 355834-71-8P
355834-72-9P 355834-73-0P 355834-74-1P
355834-75-2P 355834-76-3P 355834-77-4P
355834-78-5P 355834-79-6P 355834-80-9P
355834-81-0P 355834-82-1P 355834-84-3P
355834-85-4P 355834-86-5P 355834-87-6P
355834-88-7P 355834-98-9P 355834-99-0P
355835-00-6P 355835-01-7P 355835-02-8P
355835-03-9P 355835-04-0P 355835-05-1P
355835-06-2P 355835-07-3P 355835-08-4P
355835-09-5P 355835-10-8P 355835-11-9P
355835-12-0P 355835-14-2P 355835-15-3P
355835-16-4P 355835-17-5P 355835-18-6P
355835-19-7P 355835-20-0P 355835-21-1P
355835-22-2P 355835-23-3P 355835-24-4P
355835-25-5P 355835-27-7P 355835-30-2P
355835-31-3P 355835-32-4P 355835-33-5P
355835-34-6P 355835-35-7P 355835-36-8P
355835-37-9P 355835-38-0P 355835-41-5P
355835-42-6P 355835-43-7P 355835-44-8P
355835-45-9P 355835-46-0P 355835-47-1P
355835-49-3P 355835-50-6P 355835-51-7P
355835-52-8P 355835-55-1P 355835-56-2P
355835-57-3P 355835-58-4P 355835-59-5P

355835-60-8P 355835-61-9P 355835-62-0P
355835-63-1P 355835-64-2P 355835-65-3P
355835-66-4P 355835-67-5P 355835-68-6P
355835-69-7P 355835-97-1P 355835-98-2P
355835-99-3P 355836-00-9P 355836-01-0P
355836-02-1P 355836-03-2P 355836-04-3P
355836-39-4P 355836-40-7P 355836-41-8P
355836-42-9P 355836-44-1P 355836-45-2P
355836-46-3P 355836-47-4P 355836-48-5P
355836-49-6P 355836-53-2P 355836-54-3P
355836-55-4P 355836-56-5P 355836-57-6P
355836-58-7P 355836-59-8P 355836-61-2P
355836-62-3P 355836-63-4P 355836-64-5P
355836-65-6P 355836-67-8P 355836-68-9P
355836-69-0P 355836-71-4P 355836-72-5P
355836-73-6P 355836-74-7P 355836-75-8P
355836-76-9P 355836-77-0P 355836-78-1P
355836-79-2P 355836-80-5P 355836-81-6P
355836-83-8P 355836-84-9P 355836-86-1P
355836-87-2P 355836-88-3P 355836-89-4P
355836-90-7P 355836-91-8P 355836-95-2P
355836-99-6P 355837-00-2P 355837-02-4P
355837-23-9P 355839-94-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of substituted arylpyrazines and their binding with CRF1 receptors)


RN 355834-36-5 CAPLUS

CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-N-(1-ethylpropyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355834-37-6 CAPLUS


CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)



RN 355834-38-7 CAPLUS


CN Pyrazinamine, N-(1-ethylpropyl)-5-(4-methoxy-2-methylphenyl)-3,6-dimethyl-
(9CI) (CA INDEX NAME)

RN 355834-39-8 CAPLUS

CN Pyrazinamine, 5-(3-chlorophenyl)-N-(1-ethylpropyl)-3,6-dimethyl- (9CI)
(CA INDEX NAME)


RN 355834-40-1 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[1-(methoxymethyl)propyl]-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355834-41-2 CAPLUS


CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-N-[1-(methoxymethyl)propyl]-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355834-44-5 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-dimethyl-N-(1-propylbutyl)- (9CI)
(CA INDEX NAME)

RN 355834-45-6 CAPLUS


CN Pyrazinamine, 5-(4-methoxy-2-methylphenyl)-3,6-dimethyl-N-(1-propylbutyl)-
(9CI) (CA INDEX NAME)

RN 355834-46-7 CAPLUS

CN Pyrazinamine, 5-(4-chloro-2-methylphenyl)-3,6-dimethyl-N-(1-propylbutyl)-
(9CI) (CA INDEX NAME)


RN 355834-47-8 CAPLUS

CN Pyrazinamine, 5-[4-(dimethylamino)-2-(trifluoromethyl)phenyl]-3,6-dimethyl-N-(1-propylbutyl)-(9CI) (CA INDEX NAME)




RN 355834-48-9 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-dimethyl-N-(3-phenylpropyl)-(9CI) (CA INDEX NAME)




RN 355834-49-0 CAPLUS

CN Pyrazinamine, 5-(4-methoxy-2-methylphenyl)-3,6-dimethyl-N-(3-phenylpropyl)-(9CI) (CA INDEX NAME)




RN 355834-50-3 CAPLUS

CN Pyrazinamine, 5-(2-chloro-4-methylphenyl)-3,6-dimethyl-N-(3-phenylpropyl)-(9CI) (CA INDEX NAME)




RN 355834-51-4 CAPLUS

CN Pyrazinamine, 5-[4-(dimethylamino)-2-(trifluoromethyl)phenyl]-3,6-dimethyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-52-5 CAPLUS

CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-dimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 355834-53-6 CAPLUS

CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-dimethyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-54-7 CAPLUS


CN Pyrazinamine, 5-(4-chloro-2-methylphenyl)-N-(1-ethylpropyl)-3,6-dimethyl-
(9CI) (CA INDEX NAME)

RN 355834-55-8 CAPLUS

CN Pyrazinamine, 5-[4-(dimethylamino)-2-(trifluoromethyl)phenyl]-N-(1-ethylpropyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355834-57-0 CAPLUS

CN Pyrazinamine, 3-ethyl-N-(1-ethylpropyl)-6-methyl-5-(2,4,6-trimethylphenyl)-
(9CI) (CA INDEX NAME)


RN 355834-58-1 CAPLUS

CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI)
(CA INDEX NAME)




RN 355834-59-2 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[1-(methoxymethyl)propyl]- (9CI) (CA INDEX NAME)




RN 355834-60-5 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-61-6 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(1-phenylethyl)- (9CI) (CA INDEX NAME)




RN 355834-62-7 CAPLUS


CN Pyrazinamine, 5-(4-chloro-2-methylphenyl)-3,6-diethyl-N-(1-propylbutyl)-
(9CI) (CA INDEX NAME)

RN 355834-63-8 CAPLUS

CN Pyrazinamine, 5-(4-chloro-2-methylphenyl)-3,6-diethyl-N-[1-(methoxymethyl)propyl]- (9CI) (CA INDEX NAME)




RN 355834-64-9 CAPLUS


CN Pyrazinamine, 5-(4-chloro-2-methylphenyl)-3,6-diethyl-N-(1-methylpropyl)-
(9CI) (CA INDEX NAME)

RN 355834-65-0 CAPLUS


CN Pyrazinamine, 5-(4-chloro-2-methylphenyl)-3,6-diethyl-N-(1-phenylethyl)-
(9CI) (CA INDEX NAME)




RN 355834-66-1 CAPLUS

CN Pyrazinamine, 3,6-diethyl-5-(4-methoxy-2-methylphenyl)-N-(1-propylbutyl)-
(9CI) (CA INDEX NAME)


RN 355834-67-2 CAPLUS

CN Pyrazinamine, 3,6-diethyl-5-(4-methoxy-2-methylphenyl)-N-[1-(methoxymethyl)propyl]-
(9CI) (CA INDEX NAME)

RN 355834-68-3 CAPLUS


CN Pyrazinamine, 3,6-diethyl-5-(4-methoxy-2-methylphenyl)-N-(1-methylpropyl)-
(9CI) (CA INDEX NAME)

RN 355834-69-4 CAPLUS

CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-diethyl-N-(1-propylbutyl)- (9CI)
(CA INDEX NAME)


RN 355834-70-7 CAPLUS

CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-diethyl-N-[1-(methoxymethyl)propyl]- (9CI) (CA INDEX NAME)




RN 355834-71-8 CAPLUS

CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-diethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-72-9 CAPLUS

CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-diethyl-N-(1-phenylethyl)- (9CI)
(CA INDEX NAME)




RN 355834-73-0 CAPLUS

CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-diethyl-N-(phenylmethyl)- (9CI)
(CA INDEX NAME)




RN 355834-74-1 CAPLUS

CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-diethyl-N-(2-methyl-1-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-75-2 CAPLUS

CN Pyrazinamine, 5-[2-chloro-4-(dimethylamino)phenyl]-3,6-diethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 355834-76-3 CAPLUS

CN Pyrazinamine, 5-[2-chloro-4-(dimethylamino)phenyl]-3,6-diethyl-N-[1-(methoxymethyl)propyl]- (9CI) (CA INDEX NAME)




RN 355834-77-4 CAPLUS

CN Pyrazinamine, 5-[2-chloro-4-(dimethylamino)phenyl]-3,6-diethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-78-5 CAPLUS

CN Pyrazinamine, 5-[2-chloro-4-(dimethylamino)phenyl]-3,6-diethyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-79-6 CAPLUS

CN Pyrazinamine, 5-[2-chloro-4-(dimethylamino)phenyl]-3,6-diethyl-N-(1-phenylethyl)- (9CI) (CA INDEX NAME)




RN 355834-80-9 CAPLUS

CN Pyrazinamine, 5-[4-(dimethylamino)-2-(trifluoromethyl)phenyl]-3,6-diethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 355834-81-0 CAPLUS

CN Pyrazinamine, 5-[4-(dimethylamino)-2-(trifluoromethyl)phenyl]-3,6-diethyl-N-[1-(methoxymethyl)propyl]- (9CI) (CA INDEX NAME)




RN 355834-82-1 CAPLUS

CN Pyrazinamine, 5-[4-(dimethylamino)-2-(trifluoromethyl)phenyl]-3,6-diethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-84-3 CAPLUS

CN Pyrazinamine, N-(1-ethylpropyl)-5-(2-methoxy-4,6-dimethylphenyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355834-85-4 CAPLUS

CN Pyrazinamine, 3,6-diethyl-5-(2-methoxy-4,6-dimethylphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 355834-86-5 CAPLUS

CN Pyrazinamine, 3,6-diethyl-5-(2-methoxy-4,6-dimethylphenyl)-N-(2-methyl-1-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-87-6 CAPLUS

CN Pyrazinamine, 3,6-diethyl-5-(2-methoxy-4,6-dimethylphenyl)-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 355834-88-7 CAPLUS

CN Pyrazinamine, 3,6-diethyl-5-(2-methoxy-4,6-dimethylphenyl)-N-[1-(methoxymethyl)propyl]- (9CI) (CA INDEX NAME)



RN 355834-98-9 CAPLUS


CN Pyrazinamine, 5-[2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-N-(1-ethylpropyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)



RN 355834-99-0 CAPLUS


CN Pyrazinamine, 5-[2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-3,6-

dimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 355835-00-6 CAPLUS

CN Pyrazinamine, 5-[2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-N-[1-(methoxymethyl)propyl]-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355835-01-7 CAPLUS

CN Pyrazinamine, 5-[2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-3,6-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 355835-02-8 CAPLUS

CN Pyrazinamine, 5-[2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355835-03-9 CAPLUS

CN Pyrazinamine, 5-[2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-3,6-diethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 355835-04-0 CAPLUS

CN Pyrazinamine, 5-[2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-3,6-diethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 355835-05-1 CAPLUS

CN Pyrazinamine, N-butyl-5-[2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-N,3,6-triethyl- (9CI) (CA INDEX NAME)




RN 355835-06-2 CAPLUS

CN Pyrazinamine, 5-[2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-3,6-diethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 355835-07-3 CAPLUS

CN Pyrazinamine, 5-[2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-3,6-diethyl-N-[1-(methoxymethyl)propyl]- (9CI) (CA INDEX NAME)




RN 355835-08-4 CAPLUS

CN Pyrazinamine, N-(cyclopropylmethyl)-5-[2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-3,6-diethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 355835-09-5 CAPLUS

CN Pyrazinamine, 5-[2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-N,3,6-triethyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 355835-10-8 CAPLUS

CN Pyrazinamine, 3-bromo-6-chloro-5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355835-11-9 CAPLUS

CN Pyrazinamine, 6-chloro-5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-3-(2-propenyl)- (9CI) (CA INDEX NAME)




RN 355835-12-0 CAPLUS

CN Pyrazinamine, 6-chloro-5-(2,4-dichlorophenyl)-3-ethyl-N-(1-ethylpropyl)-
(9CI) (CA INDEX NAME)




RN 355835-14-2 CAPLUS

CN Pyrazinamine, 3-bromo-5-(2,4-dichlorophenyl)-6-ethyl-N-(1-ethylpropyl)-
(9CI) (CA INDEX NAME)




RN 355835-15-3 CAPLUS


CN Pyrazinamine, 5-(2,4-dichlorophenyl)-6-ethyl-N-(1-ethylpropyl)-3-fluoro-
(9CI) (CA INDEX NAME)




RN 355835-16-4 CAPLUS

CN Pyrazinamine, 3-chloro-5-(2,4-dichlorophenyl)-6-ethyl-N-(1-ethylpropyl)-
(9CI) (CA INDEX NAME)

RN 355835-17-5 CAPLUS


CN Pyrazinamine, 5-(2,4-dichlorophenyl)-6-ethyl-N-(1-ethylpropyl)-3-iodo-
(9CI) (CA INDEX NAME)

RN 355835-18-6 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-6-ethyl-N-(1-ethylpropyl)-3-methoxy-
(9CI) (CA INDEX NAME)


RN 355835-19-7 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3-ethyl-N-(1-ethylpropyl)-6-methyl-
(9CI) (CA INDEX NAME)




RN 355835-20-0 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-6-ethyl-N-(1-ethylpropyl)-3-methyl-
(9CI) (CA INDEX NAME)




RN 355835-21-1 CAPLUS

CN Pyrazinamine, 3-bromo-5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-6-methoxy-
(9CI) (CA INDEX NAME)




RN 355835-22-2 CAPLUS


CN Pyrazinamine, 6-chloro-5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-3-methoxy-
(9CI) (CA INDEX NAME)




RN 355835-23-3 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-3-methoxy-6-methyl-
(9CI) (CA INDEX NAME)

RN 355835-24-4 CAPLUS


CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-N-(1-ethylpropyl)-3-methoxy-6-methyl-
(9CI) (CA INDEX NAME)

RN 355835-25-5 CAPLUS

CN Pyrazinamine, N-(1-ethylpropyl)-3-methoxy-5-(4-methoxy-2-methylphenyl)-6-methyl-
(9CI) (CA INDEX NAME)


RN 355835-27-7 CAPLUS

CN Pyrazinamine, 3-ethyl-N-(1-ethylpropyl)-5-[2-methoxy-4-(trifluoromethoxy)phenyl]-6-(methylthio)- (9CI) (CA INDEX NAME)




RN 355835-30-2 CAPLUS

CN 1-Butanol, 2-[[5-(2,4-dichlorophenyl)-3,6-dimethylpyrazinyl]amino] - (9CI)
(CA INDEX NAME)




RN 355835-31-3 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-[2-methoxy-4-(trifluoromethoxy)phenyl] - (9CI) (CA INDEX NAME)




RN 355835-32-4 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-[4-methoxy-2-(trifluoromethoxy)phenyl] - (9CI) (CA INDEX NAME)




RN 355835-33-5 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-[2-methoxy-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 355835-34-6 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-[4-methoxy-2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 355835-35-7 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(2-methoxy-4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 355835-36-8 CAPLUS

CN Pyrazinamine, 5-[2,4-bis(trifluoromethoxy)phenyl]-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355835-37-9 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(4-methoxy-2-methylphenyl)-
(9CI) (CA INDEX NAME)




RN 355835-38-0 CAPLUS

CN Pyrazinamine, 5-(4-chloro-2-methylphenyl)-3,6-diethyl-N-(1-ethylpropyl)-
(9CI) (CA INDEX NAME)




RN 355835-41-5 CAPLUS

CN Pyrazinamine, 3,6-diethyl-5-(2-methoxy-4,6-dimethylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]- (9CI) (CA INDEX NAME)




RN 355835-42-6 CAPLUS

CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-diethyl-N-[2-methoxy-1-(methoxymethyl)ethyl]- (9CI) (CA INDEX NAME)




RN 355835-43-7 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[2-methoxy-1-(methoxymethyl)ethyl]- (9CI) (CA INDEX NAME)




RN 355835-44-8 CAPLUS

CN Pyrazinamine, 5-[2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-3,6-diethyl-N-[2-methoxy-1-(methoxymethyl)ethyl]- (9CI) (CA INDEX NAME)




RN 355835-45-9 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(4-fluoro-2-methylphenyl)-
(9CI) (CA INDEX NAME)




RN 355835-46-0 CAPLUS


CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N,N-bis(2-methoxyethyl)-
(9CI) (CA INDEX NAME)



RN 355835-47-1 CAPLUS


CN Pyrazinamine, N-(cyclopropylmethyl)-5-(2,4-dichlorophenyl)-3,6-diethyl-N-propyl-
(9CI) (CA INDEX NAME)






RN 355835-49-3 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-[2-methoxy-4,6-bis(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 355835-50-6 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(dicyclopropylmethyl)-3,6-diethyl- (9CI) (CA INDEX NAME)




RN 355835-51-7 CAPLUS


CN 1,2-Propanediamine, N2-[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]-N1,N1-dimethyl- (9CI) (CA INDEX NAME)




RN 355835-52-8 CAPLUS

CN Pyrazinamine, N-(dicyclopropylmethyl)-5-(2,4-dimethoxyphenyl)-3,6-diethyl-
(9CI) (CA INDEX NAME)

RN 355835-55-1 CAPLUS


CN 1,2-Ethanediamine, N-[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]-N',N'-
dimethyl-N-propyl- (9CI) (CA INDEX NAME)

RN 355835-56-2 CAPLUS

CN Pyrazinamine, 5-(2,4-diethoxyphenyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI)
(CA INDEX NAME)


RN 355835-57-3 CAPLUS

CN Phenol, 2-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-5-methoxy- (9CI)
(CA INDEX NAME)




RN 355835-58-4 CAPLUS

CN Phenol, 2-[3,6-diethyl-5-[(1-ethylpropyl)aminopyrazinyl]-5-ethoxy- (9CI)
(CA INDEX NAME)




RN 355835-59-5 CAPLUS

CN Phenol, 2-[3,6-diethyl-5-[(1-ethylpropyl)aminopyrazinyl]-5-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 355835-60-8 CAPLUS

CN Phenol, 2-[3,6-diethyl-5-[(1-ethylpropyl)aminopyrazinyl]-5-(difluoromethoxy)- (9CI) (CA INDEX NAME)




RN 355835-61-9 CAPLUS

CN Phenol, 4-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-3-methoxy- (9CI)
(CA INDEX NAME)


RN 355835-62-0 CAPLUS

CN Pyrazinamine, 5-(4-ethoxy-2-methoxyphenyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355835-63-1 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-[2-methoxy-4-(1-methylethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 355835-64-2 CAPLUS

CN Pyrazinamine, 5-[2,4-bis(1-methylethoxy)phenyl]-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355835-65-3 CAPLUS

CN Pyrazinamine, 5-[2,4-bis(diisopropylmethoxy)phenyl]-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355835-66-4 CAPLUS

CN Phenol, 2-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 355835-67-5 CAPLUS

CN Ethanol, 2-[2-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-5-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 355835-68-6 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-[2-(2-methoxyethoxy)-4-methylphenyl]- (9CI) (CA INDEX NAME)




RN 355835-69-7 CAPLUS

CN Pyrazinamine, 5-[2-[2-(dimethylamino)ethoxy]-4-methylphenyl]-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355835-97-1 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3-ethoxy-6-ethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355835-98-2 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-3,6-dimethoxy- (9CI) (CA INDEX NAME)




RN 355835-99-3 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3-ethyl-N-(1-ethylpropyl)-6-methoxy-
(9CI) (CA INDEX NAME)




RN 355836-00-9 CAPLUS

CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3-ethyl-N-(1-ethylpropyl)-6-methoxy-
(9CI) (CA INDEX NAME)




RN 355836-01-0 CAPLUS

CN Pyrazinamine, 3-ethyl-N-(1-ethylpropyl)-6-methoxy-5-[4-methoxy-2-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




Print selected from 09788315.trn


CN Pyrazinamine, 3-ethyl-N-(1-ethylpropyl)-6-methoxy-5-[2-methoxy-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




CN Pyrazinamine, 3-ethyl-N-(1-ethylpropyl)-6-methoxy-5-[2-methoxy-4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



CN	Pyrazinamine, N-(1-ethylpropyl)-3,6-dimethyl-5-(2,4,6-trichlorophenyl)- (9CI) (CA INDEX NAME)
----	--




CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-6-ethyl-N-(1-ethylpropyl)-3-methoxy-
(9CI) (CA INDEX NAME)




RN 355836-40-7 CAPLUS

CN Pyrazinamine, 5-[4-bromo-2-(trifluoromethoxy)phenyl]-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355836-41-8 CAPLUS

CN Pyrazinamine, 5-(4-chloro-2-methylphenyl)-6-ethyl-N-(1-ethylpropyl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 355836-42-9 CAPLUS


CN Pyrazinamine, 5-[2-chloro-4-(trifluoromethyl)phenyl]-6-ethyl-N-(1-ethylpropyl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 355836-44-1 CAPLUS
CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 355836-45-2 CAPLUS
CN Pyrazinamine, 5-[4-chloro-2-(trifluoromethyl)phenyl]-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)



RN 355836-46-3 CAPLUS
CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-6-ethyl-N-(1-ethylpropyl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 355836-47-4 CAPLUS
CN Pyrazinamine, 5-(2,6-dichloro-4-methoxyphenyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355836-48-5 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(3-methyl[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)




RN 355836-49-6 CAPLUS

CN Pyrazinamine, 5-[2,4-bis(trifluoromethyl)phenyl]-6-ethyl-N-(1-ethylpropyl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 355836-53-2 CAPLUS

CN Pyrazinamine, 5-[4-chloro-2-(trifluoromethyl)phenyl]-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)




RN 355836-54-3 CAPLUS

CN Pyrazinamine, N-(1-ethylpropyl)-3-methoxy-5-[2-methoxy-4-(trifluoromethoxy)phenyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 355836-55-4 CAPLUS

CN Pyrazinamine, 5-[4-chloro-2-(trifluoromethyl)phenyl]-6-ethyl-N-(1-ethylpropyl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 355836-56-5 CAPLUS

CN Pyrazinamine, 3-ethyl-N-(1-ethylpropyl)-6-methoxy-5-[2-methyl-4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 355836-57-6 CAPLUS

CN Pyrazinamine, 5-(2,4-dimethylphenyl)-6-ethyl-N-(1-ethylpropyl)-3-methoxy-
(9CI) (CA INDEX NAME)


RN 355836-58-7 CAPLUS

CN Pyrazinamine, 5-(2-chloro-4-ethoxyphenyl)-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)




RN 355836-59-8 CAPLUS

CN Carbonodithioic acid, O-[3-chloro-4-[5-[(1-ethylpropyl)amino]-6-methoxy-3-methylpyrazinyl]phenyl] S-propyl ester (9CI) (CA INDEX NAME)




RN 355836-61-2 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(4-fluoro-2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 355836-62-3 CAPLUS

CN Pyrazinamine, 5-(2-chloro-4-methylphenyl)-3,6-diethyl-N-(1-ethylpropyl)-
(9CI) (CA INDEX NAME)




RN 355836-63-4 CAPLUS

CN Pyrazinamine, 5-(4-chloro-2-methoxyphenyl)-3,6-diethyl-N-(1-ethylpropyl)-
(9CI) (CA INDEX NAME)




RN 355836-64-5 CAPLUS

CN Carbonodithioic acid, O-[3-chloro-4-[3,6-diethyl-5-[(1-ethylpropyl)aminopyrazinyl]phenyl] S-propyl ester (9CI) (CA INDEX NAME)




RN 355836-65-6 CAPLUS

CN Pyrazinamine, 5-(4-chloro-2,6-dimethoxyphenyl)-3-ethoxy-N-(1-ethylpropyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 355836-67-8 CAPLUS

CN Pyrazinamine, 5-[4-(1,3-dioxolan-2-yl)-2,6-dimethoxyphenyl]-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)




RN 355836-68-9 CAPLUS

CN Pyrazinamine, 5-(4-ethoxy-2,6-dimethoxyphenyl)-3-ethyl-N-(1-ethylpropyl)-6-methoxy- (9CI) (CA INDEX NAME)




RN 355836-69-0 CAPLUS

CN Pyrazinamine, 5-(2,6-dimethoxy-4-methylphenyl)-6-ethyl-N-(1-ethylpropyl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 355836-71-4 CAPLUS

CN Benzenemethanol, 4-[3-ethyl-5-[(1-ethylpropyl)amino]-6-methoxypyrazinyl]-3,5-dimethoxy-.alpha.,.alpha.-dimethyl- (9CI) (CA INDEX NAME)




RN 355836-72-5 CAPLUS

CN Pyrazinamine, 5-(4-chloro-2-ethoxyphenyl)-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)




RN 355836-73-6 CAPLUS

CN Pyrazinamine, 3-ethyl-5-(2-ethyl-4-methoxyphenyl)-N-(1-ethylpropyl)-6-methoxy- (9CI) (CA INDEX NAME)




RN 355836-74-7 CAPLUS

CN Pyrazinamine, 5-(4-chloro-2-methoxyphenyl)-3-ethyl-N-(1-ethylpropyl)-6-methoxy- (9CI) (CA INDEX NAME)




RN 355836-75-8 CAPLUS

CN Pyrazinamine, 5-[2-chloro-4-(1-methylethoxy)phenyl]-3-ethyl-N-(1-ethylpropyl)-6-methoxy- (9CI) (CA INDEX NAME)




RN 355836-76-9 CAPLUS

CN Pyrazinamine, 5-[2-chloro-4-(1-ethylpropoxy)phenyl]-6-ethyl-N-(1-ethylpropyl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 355836-77-0 CAPLUS

CN Pyrazinamine, 5-[2-chloro-4-(1-ethylpropoxy)phenyl]-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)




RN 355836-78-1 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-6-methoxy-3-methyl-
(9CI) (CA INDEX NAME)




RN 355836-79-2 CAPLUS


CN Pyrazinamine, 5-[2'-chloro-4',5-bis(trifluoromethyl)[1,1'-biphenyl]-2-yl]-
N-(1-ethylpropyl)-6-methoxy-3-methyl- (9CI) (CA INDEX NAME)



RN 355836-80-5 CAPLUS


CN Pyrazinamine, N-(1-ethylpropyl)-5-(4-fluoro-2-methoxyphenyl)-6-methoxy-3-
methyl- (9CI) (CA INDEX NAME)






RN 355836-81-6 CAPLUS

CN Pyrazinamine, 5-(2,4-dimethylphenyl)-N-(1-ethylpropyl)-6-methoxy-3-methyl- (9CI) (CA INDEX NAME)




RN 355836-83-8 CAPLUS

CN Pyrazinamine, 5-[4-ethoxy-2-(1-methylethoxy)phenyl]-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)




RN 355836-84-9 CAPLUS

CN Pyrazinamine, 5-[2-chloro-4-(1-ethylpropoxy)phenyl]-3-ethyl-N-(1-ethylpropyl)-6-methoxy- (9CI) (CA INDEX NAME)




RN 355836-86-1 CAPLUS

CN Pyrazinamine, N-(1-ethylpropyl)-5-[4-(1-fluoroethyl)-2,6-dimethoxyphenyl]-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)




RN 355836-87-2 CAPLUS

CN Pyrazinamine, 5-[2-chloro-4-(2-methoxyethoxy)phenyl]-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)




RN 355836-88-3 CAPLUS

CN Pyrazinamine, 5-[4-(difluoromethoxy)-2-methoxyphenyl]-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)




RN 355836-89-4 CAPLUS

CN Pyrazinamine, 5-[4-[(dimethylamino)methyl]-2-methoxyphenyl]-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)




RN 355836-90-7 CAPLUS

CN Benzenemethanol, 4-[5-[(1-ethylpropyl)amino]-6-methoxy-3-methylpyrazinyl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 355836-91-8 CAPLUS

CN Pyrazinamine, 5-[4-(difluoromethoxy)-2-methoxyphenyl]-3-ethyl-N-(1-ethylpropyl)-6-methoxy- (9CI) (CA INDEX NAME)




RN 355836-95-2 CAPLUS


CN Pyrazinamine, N-(1-ethylpropyl)-3-methoxy-5-[2-methoxy-4-(1-methylethoxy)phenyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 355836-99-6 CAPLUS
CN Phenol, 4-[3-ethyl-5-[(1-ethylpropyl)amino]-6-methoxypyrazinyl]-3-methoxy-
(9CI) (CA INDEX NAME)




RN 355837-00-2 CAPLUS
CN Pyrazinamine, 6-ethyl-N-(1-ethylpropyl)-3-methoxy-5-[2-methoxy-4-(1-methylethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 355837-02-4 CAPLUS
CN Pyrazinamine, 3-ethyl-N-(1-ethylpropyl)-5-[4-fluoro-2-(trifluoromethyl)phenyl]-6-methoxy- (9CI) (CA INDEX NAME)




RN 355837-23-9 CAPLUS
CN Pyrazinamine, 5-[2-chloro-4-(dimethylamino)phenyl]-3,6-diethyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 355839-94-0 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(1-methylpropyl)- (9CI)
(CA INDEX NAME)




IT 355836-20-3P 355836-29-2P 355836-35-0P
355836-36-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(prepn. of substituted arylpyrazines and their binding with CRF1
receptors)


RN 355836-20-3 CAPLUS

CN Pyrazinamine, 3-bromo-5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-6-methyl-
(9CI) (CA INDEX NAME)




RN 355836-29-2 CAPLUS

CN Pyrazinamine, 6-chloro-3-ethyl-N-(1-ethylpropyl)-5-[2-methoxy-4-
(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 355836-35-0 CAPLUS

CN Pyrazinamine, 3-bromo-6-methoxy-N-[(4-methoxyphenyl)methyl]-5-[2-methoxy-4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 355836-36-1 CAPLUS

CN Pyrazinamine, 3-ethyl-6-methoxy-N-[(4-methoxyphenyl)methyl]-5-[2-methoxy-4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
GI




I


AB Effects of conformation rigidity and H-bonding with the emitter coelenteramide, on the chemiluminescence efficiency of coelenterazine (I) were examd. with several coelenterazine analogs. Conformational rigidity has a light-enhancing effect, whereas decreasing light yield was obsd. by H-bond formation with the emitter.

ACCESSION NUMBER: 1991:101506 CAPLUS
DOCUMENT NUMBER: 114:101506
TITLE: Synthesis and chemiluminescence of coelenterazine (Oplophorus luciferin) analogs
AUTHOR(S): Teranishi, Katsunori; Goto, Toshio
CORPORATE SOURCE: Fac. Agric., Nagoya Univ., Nagoya, 464, Japan
SOURCE: Bulletin of the Chemical Society of Japan (1990), 63(11), 3132-40
CODEN: BCSJA8; ISSN: 0009-2673
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 114:101506


IT 132063-58-2P 132063-62-8P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (prepn. and chemiluminescence spectrum of)
RN 132063-58-2 CAPLUS
CN Benzeneacetamide, 4-hydroxy-N-[5-(4-hydroxyphenyl)-6-methyl-3-(phenylmethyl)pyrazinyl]- (9CI) (CA INDEX NAME)



RN 132063-62-8 CAPLUS
CN Benzeneacetamide, 4-hydroxy-N-[6-(2-hydroxyethyl)-5-(4-hydroxyphenyl)-3-(phenylmethyl)pyrazinyl]- (9CI) (CA INDEX NAME)




IT 132063-77-5P 132063-80-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (prepn. and intramol. cyclocondensation of, imidazopyrazine from)
RN 132063-77-5 CAPLUS
CN Tyrosine, N-[5-(4-hydroxyphenyl)-6-methyl-3-(phenylmethyl)pyrazinyl]- (9CI) (CA INDEX NAME)



RN 132063-80-0 CAPLUS

CN Tyrosine, N-[6-(2-hydroxyethyl)-5-(4-hydroxyphenyl)-3-(phenylmethyl)pyrazinyl]- (9CI) (CA INDEX NAME)




IT 132063-87-7P


RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 132063-87-7 CAPLUS

CN Tyrosine, N-[5-(4-hydroxyphenyl)-6-methyl-3-(phenylmethyl)pyrazinyl]-, methyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
GI





AB 2-Pyrazinecarbonitriles, I (R1 = H, CN, or NHPr; R2 or R3 = NHPr or substituted Ph) were prepd. and their herbicidal activity was related to their structure. For example, 6-phenyl-5-propylamino-2-pyrazinecarbonitrile (II) [82825-73-8] was prepd. by hydrolysis of 6-phenyl-5-propylamino-2,3-pyrazinedicarbonitrile [72113-09-8] with NaOH, followed by decarboxylation and treatment with POCl3. II (20 g/are) completely killed barnyard grass and broadleaf weeds. The compds. having no CN group on the pyrazine ring were inactive even at 200 g/are, e.g., 3,5-bis(propylamino)-6-phenyl-2-pyrazinecarboxamide [90688-06-5].

ACCESSION NUMBER: 1984:505696 CAPLUS
 DOCUMENT NUMBER: 101:105696
 TITLE: Studies on herbicidal 2,3-pyrazinedicarbonitriles (2,3-dicyanopyrazines). Part IV. Synthesis and herbicidal activity of 6-phenyl-5-propylamino-2-pyrazinecarbonitriles and related compounds
 AUTHOR(S): Nakamura, Akira; Ono, Matsuo; Segawa, Hirozo; Takematsu, Tetsuo
 CORPORATE SOURCE: Res. Lab., Kyowa Gas Chem. Ind. Co., Ltd., Nakajo, 959-26, Japan
 SOURCE: Agricultural and Biological Chemistry (1984), 48(4), 1009-16
 CODEN: ABCHA6; ISSN: 0002-1369
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 90688-05-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. and hydrolysis of)
 RN 90688-05-4 CAPLUS
 CN Pyrazinecarbonitrile, 6-phenyl-3,5-bis(propylamino)- (9CI) (CA INDEX NAME)



IT 90688-06-5P
 RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of, as herbicide)
 RN 90688-06-5 CAPLUS
 CN Pyrazinecarboxamide, 6-phenyl-3,5-bis(propylamino)- (9CI) (CA INDEX NAME)





=> d his

(FILE 'HOME' ENTERED AT 08:37:59 ON 29 JAN 2004)

FILE 'REGISTRY' ENTERED AT 08:38:10 ON 29 JAN 2004

L1 STRUCTURE UPLOADED

L2 5 S L1

L3 283 S L1 FUL

FILE 'CAPLUS' ENTERED AT 08:39:00 ON 29 JAN 2004

L4 6 S L3

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

31.17

186.80

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-4.16

-4.16

STN INTERNATIONAL LOGOFF AT 08:42:50 ON 29 JAN 2004